oral hGnRH-R hormone receptor antagonist

to treat of uterine fibroids, Ph. I completed

from cell-based 2.5M cmpd HTS + opt.

J. Med. Chem., Oct. 22, 2020 issue

Bayer AG, Berlin, DE

BAY-1214784

October’s molecule, the Bayer hGnRH-R antagonist BAY 1214784, is intended as an oral, once-daily treatment for uterine fibroids, a highly common problem in adult women that can lead to infertility. Existing…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: